Thelansis’s "Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential MOG Antibody-associated Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune inflammatory demyelinating disorder of the central nervous system associated with pathogenic MOG-IgG. The disease commonly presents with optic neuritis, transverse myelitis, or acute disseminated encephalomyelitis and may also involve the brainstem, cerebellum, or cerebral cortex. MOGAD can follow either a monophasic or relapsing course, with recurrent attacks contributing to persistent visual or neurological disability in some patients. Acute management generally relies on high-dose corticosteroids, with intravenous immunoglobulin or plasma exchange used in severe or incompletely responsive attacks, while relapse prevention may involve IVIG, rituximab, mycophenolate, azathioprine, corticosteroids, or IL-6-directed therapy. However, long-term treatment remains largely empiric, with limited comparative evidence and no approved MOGAD-specific disease-modifying therapy as of September 2026. The field is now moving toward targeted immunotherapy. In the Phase 3 METEOROID trial, satralizumab reduced the risk of relapse by 68% versus placebo, and the program received FDA Priority Review in September 2026. Meanwhile, the FcRn antagonist rozanolixizumab remains in a Phase 3 pivotal study, aiming to reduce pathogenic IgG through accelerated antibody clearance. Antigen-specific tolerance strategies remain an earlier research frontier, underscoring continued opportunity for more precise and durable immune-directed therapies.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report
Our team will get in touch with you shortly about the Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report.